Aarti Drugs Limited
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations.
What Aarti files
- Others64
- Investor Meet39
- Updates15
- Important12
- Board Meeting10
- PPTs6
Aarti Drugs filed its FY26 Sustainability Report. The company temporarily stopped a chlorosulfonation process at its T-150 unit following an HCl gas leak, per MPCB directives. It reported a Turnover of ₹2,260.39 Cr, boosting R&D/Capex for environmental and social improvements, including ZLD at 10 API facilities.
Aarti Drugs has nearly completed its Rs. 600 Cr capex, bringing new plants (Salicylic Acid, Sayakha greenfield) online, driving capacity growth and market expansion. Q1 FY26 revenue rose 6% to Rs. 591 Cr, with PAT up 63% to Rs. 54 Cr, signaling a strong rebound after FY25's slight dip.
Aarti Drugs' new manufacturing plant in Sayakha, Gujarat, began commercial production with 60 MTPd capacity for specialty chemicals. The Rs 220 Cr investment aims for backward integration, enhancing supply chain reliability, and driving margin expansion.
Aarti Drugs has announced a board meeting to review the financial results for the quarter and half-year. No new operational updates, orders, or business developments were reported.
Aarti Drugs Limited has entered into a Share Subscription and Shareholders’ Agreement with Prozeal Green Power Private Limited and Pro-Zeal Green Power Nine Private Limited. The company will acquire a 26.25% equity stake and voting rights along with compulsory convertible debentures in the latter, a Special Purpose Vehicle (SPV) aimed...